Tim Schacker
University of Minnesota
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tim Schacker as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:15 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07340047 · H1ssF Flu Vaccine Clinical TrialUniversity of Minnesota · withdrawn · Influenza · principal investigator
- N/ANCT02707926 · The Lymphoid Tissue Pharmacology of Antiretroviral DrugsUniversity of Nebraska · withdrawn · HIV Infection · principal investigator
- Ph1NCT02191098 · Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected PeopleUniversity of Minnesota · completed · HIV, Stable ART · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- HIV Reservoir Dynamics Associated with Metabolic Complications of HIV InfectionR01DK143536 · NIDDK · UNIVERSITY OF MINNESOTA · fiscal years 2025 to 2026 · $1,739,081 awarded in 2026Same name and institution; not confirmed by an ID
- Investigation of persistent HIV immune stimulation in lymphoid tissues during therapy as a cause of sustained immune activationR01AI147912 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2020 to 2024 · $735,152 awarded in 2024Same name and institution; not confirmed by an ID
- The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccinationU01AI141981 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2019 to 2023 · $649,719 awarded in 2023Same name and institution; not confirmed by an ID
- Reservoir Dynamics in Patients Treated in Very Early Acute HIV InfectionR01AI125127 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2016 to 2020 · $644,569 awarded in 2020Same name and institution; not confirmed by an ID
- Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIVU01AI105872 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2013 to 2017 · $990,702 awarded in 2017Same name and institution; not confirmed by an ID
- Antifibrotic Therapy to Improve Immune reconstitution in HIVR01AI093319 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2011 to 2014 · $610,166 awarded in 2014Same name and institution; not confirmed by an ID
- A Compartmental Analysis of HIV Reservoirs and Immune ReconstitutionP01AI074340 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2008 to 2012 · $2,069,875 awarded in 2012Same name and institution; not confirmed by an ID
- CLINICAL TRIAL: CHANGES IN LYMPHOCYTE POPULATIONS AND ARCHITECTURE BEFORE AND DUM01RR000400 · NCRR · UNIVERSITY OF MINNESOTA · fiscal years 2004 to 2008 · $28,882 awarded in 2008Same name and institution; not confirmed by an ID
- Lymph Node Inflammation and Fibrosis as a Mechanism of CD4 Loss in HIVR56AI054232 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2008 · $579,431 awarded in 2008Same name and institution; not confirmed by an ID
- Damage to the Lymphoid Niche & Timing of HIV TherapyR01AI054232 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2003 to 2007 · $461,905 awarded in 2007Same name and institution; not confirmed by an ID
- Pathogenesis of HIV Induced Lymphoid Tissue InflammationK24AI056986 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 2003 to 2007 · $138,011 awarded in 2007Same name and institution; not confirmed by an ID
- EPIDEMIOLOGY/MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSIONR01DE012934 · NIDCR · UNIVERSITY OF MINNESOTA · fiscal years 1999 to 2002 · $323,338 awarded in 2002Same name and institution; not confirmed by an ID
- SIGNIFICANCE OF HSV REACTIVATION IN HIV INFLECTIONK08AI001228 · NIAID · UNIVERSITY OF MINNESOTA · fiscal years 1994 to 1996 · $72,608 awarded in 1996Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The Lymphoid Tissue Pharmacology of Antiretroviral DrugsR01AI124965 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Courtney V Fletcher · fiscal years 2016 to 2020Named on NCT02707926
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:15 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.Nat Med · 20091,504 citationsRCR 32.7
- Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.PLoS Pathog · 2013225 citationsRCR 6.1
- Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.J Infect Dis · 2002160 citationsRCR 3.8
- Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.PLoS Pathog · 2012146 citationsRCR 3.6
- 130 citationsRCR 3.9
- Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial.Ann Intern Med · 1998123 citationsRCR 4.2
- Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.AIDS · 2002120 citationsRCR 3.4
- 112 citationsRCR 2.8
- 112 citationsRCR 4.2
- Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial.Nat Med · 2022102 citationsRCR 6.9